A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.
The study is a naturalistic study of routinely prescribed antipsychotics using outcome measures undertaken as part of the routine clinical care of the cohort. These clinical data are linked with genetic information obtained from DNA and RNA from blood samples undertaken as part of the study.
No alteration is made to the subjects treatment regime or medication.
The study is a two stage investigation:
- The first stage involves the collection of a databank of clinical information and blood samples for DNA and RNA extraction from patients treated with antipsychotic medication.
- The second stage is a molecular genetic investigation of treatment-related genetic factors that may contribute to response prediction and predisposition to side effects.
From these genetic studies pharmacogenetic prediction tests will be validated and/or developed.
|Study Design:||Observational Model: Case-Only|
|Official Title:||A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses|
|Study Start Date:||May 2008|
|Study Completion Date:||March 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Subjects treated with olanzapine as part of their routine clinical care
Subjects treated with risperidone as part of their routine clinical care
Subjects treated with quetiapine as part of their routine clinical care
Please refer to this study by its ClinicalTrials.gov identifier: NCT00701753
|Canada, British Columbia|
|Vancouver Coastal Health|
|Vancouver, British Columbia, Canada|
|Principal Investigator:||Soma Ganesan, MD||Vancouver Coastal Health|
|Study Director:||Janet Munro, MB BS||TheraGenetics Limited|